SRR23303755
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- MYOGENESIS+0.510
- INFLAMMATORY_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.490
- UV_RESPONSE_DN+0.470
- ANGIOGENESIS+0.460
- HEDGEHOG_SIGNALING+0.440
- COAGULATION+0.430
- COMPLEMENT+0.420
Top 10 suppressed
- E2F_TARGETS-0.500
- MYC_TARGETS_V2-0.430
- G2M_CHECKPOINT-0.420
- MYC_TARGETS_V1-0.410
- DNA_REPAIR-0.350
- GLYCOLYSIS-0.230
- OXIDATIVE_PHOSPHORYLATION-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.120
- ESTROGEN_RESPONSE_LATE-0.060
- MTORC1_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0419_T2_RNA | — | A | 0.941 |
| 2 | MBCProject_0734_T1A_RNA | — | A | 0.938 |
| 3 | SRR23303737 | — | — | 0.926 |
| 4 | X6e4edcae.68aa.4e0a.80bc.d8114f132bba | — | cohortMD2 | 0.918 |
| 5 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.909 |
| 6 | SRR6013602 | — | cohortMD2 | 0.907 |
| 7 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.906 |
| 8 | SRR1797296 | — | cohortMD2 | 0.904 |
| 9 | TCGA-XF-AAN8-01A-11R-A42T-07 | — | — | 0.900 |
| 10 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.590 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| MYOGENESIS | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |